375O - DIsease burden and treatment pattern of Recurrent or advanced Endometrial cancer in Korea: A naTIONwide database (DIRECTION) study

Background

Advanced or recurrent endometrial cancer (a/r EC) patients have a poor prognosis with high recurrence and mortality rate. Yet, a real-world disease burden of a/r EC is not fully elucidated. Thus, this study aimed to investigate healthcare resource utilization (HCRU), costs, and systemic anticancer therapy (SACT) patterns in these patients.

Methods

This population-based nationwide study used 15 years of Health Insurance Review & Assessment Service data (Jan. 2008 – Dec. 2022). Adult patients with newly diagnosed a/r EC were followed up for maximum 156 months from the start date of the 1^st line SACT (SACT1). Patients with aEC included those who got SACT as the initial treatment, while rEC was defined as those who initiated SACT on or after the start of 2^nd line of therapy (LoT2), following the surgery or radiation therapy (RT) in LoT1. All cause- and EC related-HCRU and costs, SACT patterns and prognosis were analyzed by descriptive analysis and Kaplan-Meier estimation.

Results

In total, 1,794 rEC and 910 aEC patients were included, and all cause- and EC related- HCRU tended to increase with increased line of SACT. EC-related inpatient visits in SACT1-3 were 0.6, 0.9, and 1.0 times per-patient-per-month (PPPM), and 7.8, 1.9, and 2.0 times PPPM for outpatient visits. As for a treatment pattern, platinum-based regimen was most commonly used (Table). From SACT1 to 3, the median values of both treatment duration (3.5, 2.8, and 2.0 months) and SACT-free interval showed decreasing trends (18.4, 5.0, and 3.2 months). EC-related cost, mostly inpatient cost, increased from 1,048 USD to 1,980 USD PPPM from SACT1 to 3 Table: 375O

Top 3 regimens in the 1st- to 3rd-line of SACT

^aP-based combinations other than T+P or D+P. ^bOther P-based combinations 10.4, hormone 7.1, non-P monotherapy 2.9 and other non-P based combinations 1.3%. ^cP 10.6, non-P monotherapy 7.7, hormone 5.5 and other non-P based combinations 1.3%. ^dHormone 13.1, P 13.1, non-P monotherapy 8.9 and other non-P based combi. 1.0% T+P, taxanes+platinum; D+P, doxorubicin+platinum; P, platinum.

Conclusions

Our study reveals an increase in HCRU and costs and a decrease in treatment duration and SACT-free interval with increased line of SACT, indicating a worsening prognosis as EC progresses. Thus, the application of appropriate treatments, including new therapeutic agents, in newly diagnosed a/r EC patients is important.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

GSK Korea Ltd.

Funding

GSK Korea Ltd.

Disclosure

H. Cho, S.I. Kim, K. Kim: Financial Interests, Institutional, Principal Investigator: GSK. M.J. Bae: Financial Interests, Institutional, Project Lead: GSK. K. Kwon, C.W. Jung, Y. Lee, J. Ahn: Financial Interests, Institutional, Speaker, Consultant, Advisor: GSK.